Clinical Trial

Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)

Study acronym: AD-MINER
Recruiting
View on ClinicalTrials.gov →
Summary
This single-center prospective cohort study will enroll 750 participants (250 cognitively Normal (CN) individuals, 250 with mild cognitive impairment (MCI), and 250 with Alzheimer's disease (AD)). At baseline and at annual follow-ups, participants will undergo 3 Tesla (3 T) and 7 Tesla (7 T) multimodal magnetic resonance imaging (MRI) scans, blood biomarker testing, genotyping, and cognitive assessments to identify early imaging biomarkers and construct models of disease progression.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-20.
Status change: Not Yet Recruiting → Recruiting 2025-08-11
Trial Details
NCT Number NCT07089303
Lead Sponsor Chinese PLA General Hospital
Conditions Alzheimer Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Enrollment 750 participants
Start Date 2025-07-01
Primary Completion 2029-07 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-14